Effects of a slowly fermentable fiber mixture against the background of a high-protein diet on insulin sensitivity and metabolic health in individuals with overweight: a randomized, placebo-controlled trial.

Gut MicrobesDec 29, 2025 (epub)
Clinical ResearchEndocrinologyGastroenterologyOpen access

Colin A J van Kalkeren, Thirza van Deuren, Miranda M J Coenjaerds et al.

✦ AI-curated · Sources linked

In 30 seconds

This 12-week randomized, placebo-controlled trial tested daily potato fiber and sugar beet pectin against maltodextrin in adults with overweight or obesity consuming a high-protein diet. The fiber group included 19 participants and the placebo group 21. Peripheral insulin sensitivity tended to decline with fiber versus placebo (p = 0.081), while whole-body insulin sensitivity significantly decreased (p = 0.034). Fiber also altered substrate oxidation and was associated with increased gut permeability and plasma interleukin-6. Body composition, microbial composition, and measured fecal and circulating metabolites were unchanged.

Key findings

  • Whole-body insulin sensitivity decreased significantly with fiber compared with placebo (p = 0.034); peripheral insulin sensitivity showed a nonsignificant tendency to decrease (p = 0.081).
  • Fiber mitigated the placebo-group increase in insulin-mediated carbohydrate oxidation (p = 0.027) and decrease in fat oxidation (p = 0.006).
  • Fiber prevented an increase in protein oxidation (p = 0.048), but increased colonic gut permeability (p = 0.046) and plasma interleukin-6 (p = 0.025).
  • Body composition, microbial composition, and fecal and circulating metabolites remained unchanged.

Why it matters

The findings challenge the assumption that increasing fermentable fiber necessarily improves metabolic health when paired with a high-protein diet. In this trial, the combination was associated with lower insulin sensitivity and changes in substrate oxidation, alongside signals of impaired gut barrier function and inflammation. These outcomes highlight the importance of considering dietary context when evaluating fiber interventions.

What to keep in mind

The trial was small, with 19 participants in the fiber group and 21 in the placebo group, and lasted 12 weeks. Its findings apply to the tested fiber mixture alongside a high-protein diet.

Source

Published in Gut Microbes. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.